A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer

JAMA Oncology

Volumn 3, Issue 8, 2017, Pages 1051-1058

  Rimm, David L ^a   Han, Gang ^b   Taube, Janis M ^c   Yi, Eunhee S ^d   Bridge, Julia A ^e   Flieder, Douglas B ^f   Homer, Robert ^a   West, William W ^e   Wu, Hong ^f   Roden, Anja C ^d   Fujimoto, Junya ^g   Yu, Hui ^h   Anders, Robert ^c   Kowalewski, Ashley ^h   Rivard, Christopher ^h   Rehman, Jamaal ⁱ   Batenchuk, Cory ^j   Burns, Virginia ^j   Hirsch, Fred R ^h   Wistuba, Ignacio I ^g  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN E1L3N; UNCLASSIFIED DRUG; ANTIBODY; CD274 PROTEIN, HUMAN;

ACCURACY; ARTICLE; BIOASSAY; COMPARATIVE STUDY; EXPERIMENTAL STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RELIABILITY; REPRODUCIBILITY; SQUAMOUS CELL LUNG CARCINOMA; TUMOR CELL; CLINICAL TRIAL; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MULTICENTER STUDY; PATHOLOGIST; PATHOLOGY; PROCEDURES;

ANTIBODIES; ANTIGENS, CD274; BIOLOGICAL ASSAY; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PATHOLOGISTS; REPRODUCIBILITY OF RESULTS;

EID: 85028949327     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.0013     Document Type: Article

References (17)

1. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26): 2455-2465.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.
3. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti–PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.
4. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907-922.
5. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12 (2):208-222.
6. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88(20):1456-1466.
7. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101 (21):1446-1452.
8. Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;6(4):284-290. doi:10.1037/1040-3590 .6.4.284
9. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
10. Legendre P. Species associations: the Kendall coefficient of concordance revisited. J Agric Biol Environ Stat. 2005;10(2):226-245. doi:10.1198 /108571105X46642
11. Phillips T, Simmons P, Inzunza HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non–small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015;23(8):541-549.
12. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
13. Velcheti V, Schalper KA, Carvajal DE, etal. Programmeddeathligand-1expressioninnon–small celllungcancer.LabInvest.2014;94(1):107-116.
14. Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372 (21):2018-2028.
15. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373 (17):1627-1639.
16. Gaule P, Smithy JW, Toki M, et al. A quantitative comparison of antibodies to programmed cell death 1 ligand 1 [published online August 18, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.3015
17. Ratcliffe MJ, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cut-offs in non-small cell lung cancer [published online January 10, 2017]. Clin Cancer Res. 2017;clincanres.2375.2016. doi:10.1158/1078-0432 .CCR-16-2375